Adaptive Biotechnologies (ADPT) to Release Earnings on Thursday

Adaptive Biotechnologies (NASDAQ:ADPT) will be issuing its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.02. Adaptive Biotechnologies had a negative return on equity of 56.58% and a negative net margin of 123.24%. The company had revenue of $41.87 million for the quarter, compared to analyst estimates of $38.78 million. During the same quarter last year, the firm posted ($0.40) EPS. The firm’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Up 3.6 %

Adaptive Biotechnologies stock opened at $4.60 on Wednesday. The company has a fifty day simple moving average of $3.64 and a 200-day simple moving average of $3.52. The firm has a market capitalization of $677.90 million, a price-to-earnings ratio of -3.09 and a beta of 1.35. Adaptive Biotechnologies has a 52-week low of $2.28 and a 52-week high of $8.51.

Wall Street Analysts Forecast Growth

Separately, BTIG Research dropped their price objective on shares of Adaptive Biotechnologies from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, April 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.80.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.